Patients with dystrophic epidermolysis bullosa had positive phase 3 results with Vyjuvek treatment, Krystal Biotech announced in a press release … Vyjuvek (investigational beremagene geperpavec) is a noninvasive, topical, redosable gene therapy … The randomized, double-blind, intra-patient, placebo-controlled phase 3 GEM-3 trial enrolled 31 patients with dystrophic epidermolysis bullosa … read more